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Abstract
Background: Exacerbations of Chronic obstructive pulmonary disease (COPD) are an important cause
of the morbidity and mortality associated with the disease. Strategies to reduce exacerbation frequency
are thus urgently required and depend on an understanding of the inflammatory milieu associated with
exacerbation episodes. Bacterial colonisation has been shown to be related to the degree of airflow
obstruction and increased exacerbation frequency. The aim of this study was to asses the kinetics of
cytokine release from COPD parenchymal explants using an ex vivo model of lipopolysaccharide (LPS)
induced acute inflammation.
Methods: Lung tissue from 24 patients classified by the GOLD guidelines (7F/17M, age 67.9 ± 2.0 yrs,
FEV1 76.3 ± 3.5% of predicted) and 13 subjects with normal lung function (8F,5M, age 55.6 ± 4.1 yrs, FEV1
98.8 ± 4.1% of predicted) was stimulated with 100 ng/ml LPS alone or in combination with either
neutralising TNFα or IL-10 antibodies and supernatant collected at 1,2,4,6,24, and 48 hr time points and
analysed for IL-1β, IL-5, IL-6, CXCL8, IL-10 and TNFα using ELISA. Following culture, explants were
embedded in glycol methacrylate and immunohistochemical staining was conducted to determine the
cellular source of TNFα, and numbers of macrophages, neutrophils and mast cells.
Results: In our study TNFα was the initial and predictive cytokine released followed by IL-6, CXCL8 and
IL-10 in the cytokine cascade following LPS exposure. The cytokine cascade was inhibited by the
neutralisation of the TNFα released in response to LPS and augmented by the neutralisation of the anti-
inflammatory cytokine IL-10. Immunohistochemical analysis indicated that TNFα was predominantly
expressed in macrophages and mast cells. When patients were stratified by GOLD status, GOLD I (n =
11) and II (n = 13) individuals had an exaggerated TNFα responses but lacked a robust IL-10 response
compared to patients with normal lung function (n = 13).
Conclusion: We report on a reliable ex vitro model for the investigation of acute lung inflammation and
its resolution using lung parenchymal explants from COPD patients. We propose that differences in the
production of both TNFα and IL-10 in COPD lung tissue following exposure to bacterial LPS may have
important biological implications for both episodes of exacerbation, disease progression and amelioration.
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Background
Chronic obstructive pulmonary disease (COPD) is a
major cause of mortality world wide and is predicted to be
the third-leading cause of death by 2020[1]. COPD is
defined by the American Thoracic society as a disease
process involving progressive chronic airflow obstruction
because of chronic bronchitis, emphysema or both[2].
Both the emphysematous destruction of lung tissue and
the enlargement of air spaces along with excessive cough
and sputum productions associated with bronchitis are
believed to be related to an exaggerated inflammatory
response[3]. Indeed the activation and infiltration of
inflammatory cells including (CD8+) T lymphocytes,
macrophages and neutrophils is a prominent feature of
COPD[4,5]. In addition to the chronic state of inflamma-
tion observed in the airway patients with COPD are also
prone to periods of exacerbation of the disease which are
an important cause of the morbidity and mortality found
in COPD [6-8]. COPD exacerbations are caused by a vari-
ety of factors such as viruses, bacteria and common pollut-
ants. COPD exacerbations are now being recognised as
important features of the natural history of COPD, as the
frequency of exacerbations is associated with the severity
of disease[9,10]. Statergies to reduce exacerbation fre-
quency are thus urgently required and depend on an
understanding of the inflammatory milieu associated
with exacerbation episodes. The precise role of bacteria in
COPD exacerbation has been difficult to asses due to
approximately 30% of stable state COPD patients having
bacterial colonisation within the airways[11]. The most
common organism isolated from COPD patients is Hae-
mophilus Influenzae and others include streptococcus pheu-
moniae  and  Bramhemella carrarhalis[11]. Bacterial
colonisation has been shown to be related to the degree of
airflow obstruction and increased exacerbation fre-
quency[9,12-14]. More recently Stockley and colleagues
have shown that COPD exacerbations associated with
purulent sputum are more likely to produce positive bac-
terial cultures than exacerbations where the sputum was
mucoid[15]. Additionally Sethi and collegues have shown
that exacerbations associated with H. influenza  and B.
catarrhalis both gram negative bacteria are associated with
significantly higher levels of inflammatory markers com-
pared to pathogen-negative exacerbations[16].
Wedzicha and colleagues have shown that stable state
COPD patients with high sputum levels of Interleukin-6
(IL-6) and CXCL8 have more numerous exacerbations,
suggesting that the frequency of exacerbations is associ-
ated with increased airway inflammation[17,18].
Cytokines such as IL-6 and CXCL8 are rarely produced
individually instead they are more usually released in
combination with other cytokines and mediators that are
characteristic of a particular disease state. These cytokine
networks exhibit great pleiotropy and redundancy to the
effect that any one cytokine may be influenced by another
released simultaneously. TNFα and IL-1β have been iden-
tified as key cytokines that are able to initiate inflamma-
tory cascades during exacerbations of chronic
inflammatory conditions such as rheumatoid arthritis,
inflammatory bowel disease, and severe asthma [19-21].
Although it is presumed that COPD exacerbations are
associated with increased airway inflammation, as in
patients with asthma, there is little information on the
nature of the inflammatory mediator milieu during an
exacerbation, especially when studied from the onset of
symptoms.
In this study we aimed to assess the kinetics of key pro-
and anti-inflammatory cytokines released from lung
parenchymal explants obtained from COPD patients,
using an ex vivo model of Gram negative Lipopolysaccha-
ride (LPS) induced acute inflammation. We found that
COPD disease severity was associated with an enhanced
ex vivo pro-inflammatory cytokine response led by TNFα
which was not ameliorated by the anti-inflammatory
cytokine IL-10.
Methods
Patient characteristics for human lung tissue experiments
Human parenchymal lung tissue was obtained from 37
patients (15F/21M) undergoing resection for carcinoma
and 1 male undergoing surgery to remove a cyst at Guy's
Hospital, London. All specimens of parenchymal tissue
were obtained from sites distant from the tumour. The
study was approved by the institutional ethics committee
and all volunteers gave informed consent. The Global Ini-
tiative for Chronic Obstructive Pulmonary Disease
(GOLD) uses a four step classification for the severity of
COPD based on measurements of airflow limitation dur-
ing forced expiration[22,23]. Each stage is determined by
the volume of air that can be forcibly exhaled in one sec-
ond (FEV1) and by the ratio of FEV1 to the forced vital
capacity (FVC); lower stages indicate less severe disease.
Using the GOLD guidelines our patient cohort was strati-
fied into the following groups, GOLD I (FEV1/FVC < 70%,
FEV1 ≥ 80% predicted), GOLD II (FEV1/FVC < 70%, 50%
≤ FEV1 < 80% predicted) and individuals with normal
lung function (FEV1/FVC > 70%, FEV1  ≥ 90% pre-
dicted)[23]. Table 1 shows the number of patients in each
GOLD stage and their demographics which include age,
gender, lung function and smoking history. For the pur-
poses of this study ex-smokers were defined as individuals
that had given up smoking for ≥ 3 years to ensure for
smoking cessation. All demography data was available up
to the date of surgery and none of the subjects were treated
prior with inhaled or oral corticosteroids or bronchodila-
tors.Respiratory Research 2008, 9:47 http://respiratory-research.com/content/9/1/47
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Preparation of human lung tissue for primary cell culture
The procedure for preparation of human lung tissue has
been described previously elsewhere[24]. Briefly, resected
lung tissue was dissected free of tumour, large airways,
pleura and visible blood vessels and finely chopped using
dissecting scissors, into 2 mm3 fragments during several
washes with Tyrode's buffer containing 0.1% sodium
bicarbonate. Six explants (total weight approx. 30 mg)
were incubated per well (2.0 cm2) of a 24 well plate with
RPMI-1640 medium containing 1% penicillin, 1% strep-
tomycin, and 1% gentamycin at 37°C in 5% carbon diox-
ide/air for 16 hours. Tissue was then either stimulated
with 100 ng/ml LPS (Sigma-Aldrich, UK) or maintained
in cell culture media alone for 1, 2, 4, 6, 24, or 48 hours.
For neutralisation of TNFα and IL-10 bioactivity, tissue
was incubated with 1 μg/ml of neutralising TNFα or IL-10
antibody or an isotype control (R&D Systems, Minneapo-
lis, USA) for 1 hr prior to stimulation with 100 ng/ml LPS.
Lung tissue fragments and supernatant were harvested at
each time point and both were stored at -80°C until anal-
ysis. The tissue fragments were weighed to determine total
tissue weight to normalize the levels of released cytokines.
Immunohistochemistry of human lung tissue
For the last 18 individuals recruited in the study the lung
explants collected (6 per experimental condition) were
embedded in glycol methacrylate (GMA), following stim-
ulation with LPS or cell culture media alone for 1 or 6 hrs,
as described above. The patient demographics which
include age, gender, lung function, GOLD stage and
smoking history as well as the mean number of macro-
phages, mast cells and lymphocytes counted for each
group determined by lung function are given in table 2. To
determine the cell types responsible for TNFα release in
response to LPS, immunohistochemical staining of the
samples was conducted as previously described[25].
Briefly, serial sections of 2 μM were stained immunohisto-
chemically using the streptavidin biotin-peroxidase detec-
tion system and murine monoclonal antibodies directed
to either human TNFα (1:100, clone 2B3A6A2, Biosource,
SA), CD68 (1:200, clone PG-M1, DAKO), mast cell tryp-
Table 1: Patient characteristics of subjects prior to the removal of lung tissue
Classification Normal Lung Function GOLD I GOLD II
FEV1/FVC > 70%
FEV1 ≥ 90%
predicted
FEV1/FVC < 70%
FEV1 ≥ 80%
predicted
FEV1/FVC < 70%
50% ≤ FEV1 < 80%
predicted
No. subjects 13 11 13
Age 55.6 ± 4.1 69.2 ± 2.9 66.9 ± 2.8
Gender 8 F
5 M
3 F
8 M
4 F
9 M
Lung function (FEV1/FVC) 0.82 ± 0.02 0.63 ± 0.03 0.59 ± 0.02
FEV1 % predicted 98.8 ± 4.1 90 ± 4.0 65.6 ± 2.4
Smoking status 6 current smokers 6 current smokers 8 current smokers
4 ex-smokers 5 ex-smokers 5 ex smokers
3 non-smokers
Tissue samples were taken from 37 patients. Patient details including age, gender, lung function given as the ratio of air that can be forcibly exhaled 
in one second (FEV1) to the forced vital capacity (FVC), FEV1/FVC and FEV1% predicted and smoking status are listed as the mean ± SEM.
Table 2: Numbers of Macrophages, Mast cells and Neutrophils in lung tissue from COPD patients and individuals with normal lung 
function
Normal lung Function (4M/6F) GOLD I/II (6M/4F) p Value
Lung function (FEV1/FVC) 0.79 ± 0.02 0.62 ± 0.03 0.05
FEV1 % predicted 99.2 ± 9.7 77.2 ± 8.5 0.05
Smoking status 4 current smokers 4 current smokers
3 ex-smokers 5 ex-smokers
2 non-smokers
Age 64.7. ± 7.9 71.2 ± 2.0 0.07
Macrophage (CD68) cell/mm2 2.8 ± 0.6 5.4 ± 1.4 0.10
Mast Cell (Tryptase) cell/mm2 20.6 ± 5.5 17.1 ± 3.9 0.23
Neutrophil (Neutrophil elastase) cell/mm2 8.1 ± 0.7 11.5 ± 3.6 0.15
Patient data including lung function given as the ratio of air that can be forcibly exhaled in one second (FEV1) to the forced vital capacity (FVC), 
FEV1/FVC and FEV1% predicted, smoking status, age and gender are listed as the mean ± SEM. Cell numbers are listed as the mean number of cells/
mm2, ± SEM and the p value obtained when comparing the each factor between the two groups is given, p < 0.05 was considered statistically 
significant.Respiratory Research 2008, 9:47 http://respiratory-research.com/content/9/1/47
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tase (1:1000, clone AA1, DAKO) or neutrophil elastase
(1:500, clone NP57, DAKO). Control sections were incu-
bated with isotype-matched immunoglobulins. The previ-
ously described camera-lucida technique was used to
determine which cells per mm2 of alveolar tissue co-local-
ised with TNFα positive staining on the serial sec-
tions[26].
Enzyme-Linked Immunosorbent Assay
The levels of each cytokine in the supernatant were meas-
ured by enzyme-linked immunosorbent assay (ELISA)
and the concentration corrected for tissue weight. Human
TNFα and IL-1β specific ELISA kits (limit of detection of
0.3 pg/mg of tissue and 0.1 pg/mg of tissue, respectively)
were purchased from R&D Systems Europe Ltd, Abing-
don, UK. Human IL-5, IL-6, CXCL8 and IL-10 were all
measured using commercially available ELISA Duosets
from Biosource Europe, SA (limits of detection 0.3 pg/mg
of tissue, 0.28 pg/mg of tissue, 0.26 pg/mg of tissue and
0.25 pg/mg of tissue, respectively). The manufacturer's
protocol was followed for each ELISA.
Lactate dehydrogenase assay
To test for tissue viability Lactate dehydrogenase (LDH)
levels were measured in lung supernatant using a com-
mercially available assay and LDH standard from Roche
(Indianapolis, USA). For a positive control, lung explants
were homogenised on ice using a XL10 sonicator set at an
amplitude of 2 microns, for 12 cycles of 10 seconds soni-
cation followed by 20 seconds rest, in 10% triton PBS
buffer containing protease inhibitor cocktail (P2714,
Sigma-Aldrich, UK). Following sonication samples were
centrifuged at 15,000 g for 15 mins at 4°C, and superna-
tant removed for storage. The limit of detection for the
assay was 1.95 ng/mg of tissue.
Statistical Analysis
All results were normalised using the tissue weight and are
expressed as the mean ± SEM. Before statistical evaluation,
all results were tested for population normality and
homogeneity of variance, and where applicable, a Student
t test was performed. A value of P < 0.05 was accepted as
significant. Differences within standard curves were ana-
lysed by ANOVA with a Tukey/Kramer post hoc correction
again a value of P < 0.05 was accepted as significant. Cor-
relations between parameters were examined for statisti-
cal significance by Spearman's correlation. Experiments
were performed on each of the patients in the cohort.
Results
Kinetics of the acute inflammatory response in human lung 
tissue
Release of the pro-inflammatory cytokine TNFα was sig-
nificantly higher in the LPS stimulated tissue as early as 1
hr, continued to rise at 2 and 4 hrs, and peaked at 6 hrs
(mean = 17.4 ± 1.5 pg/mg of tissue) compared to undetec-
table levels in the non-stimulated controls (Figure 1A).
Release of TNFα from LPS-stimulated tissue was dose-
dependant within the range of 0.1–1000 ng/ml, with a
maximal response at 1000 ng/ml therefore, in subsequent
experiments, we used a sub-maximal LPS dose of 100 ng/
ml. Over a 48 hr time period there was no change in the
levels of LDH in supernatants from LPS stimulated tissue,
compared to buffer, indicating the absence of cytotoxic
effects. While LPS can potentially activate a range of differ-
ent cell types, not all pro-inflammatory cytokines were
released. Figure 1B shows that when the tissue was stimu-
lated with LPS or buffer for 48 hrs there was no statistical
significant difference in the levels of IL-1β released.
Cytokine cascades in the acute inflammatory response
As shown in figure 2A the maximal increase of IL-6
occurred later than TNFα, peaking at 48 hrs (mean =
685.7 ± 189 pg/mg of tissue) compared to tissue chal-
lenged with buffer alone (mean = 238.3 ± 50 pg/mg of tis-
sue, P < 0.05). The release of the chemokine CXCL8
followed a similar pattern to IL-6, with a maximal
response occurring at 24 hrs (mean = 1490.4 ± 394 pg/mg
of tissue) versus tissue challenged with buffer (mean =
692.3 ± 251 pg/mg of tissue, P < 0.05) (figure 2B). The lev-
els of anti-inflammatory cytokine IL-10 were still increas-
ing between 24 hrs and 48 hrs (mean = 15.2 ± 2.4 pg/mg
of tissue) compared to undetectable levels in the tissue
challenged with buffer (P < 0.05, figure 2C). In contrast,
IL-5 was not released in response to LPS (figure 2D).
TNFα release at 6 hours predicts subsequent cytokine 
levels at 24 hours
The kinetic data indicated that a succession of cytokines
are released in response to LPS, with TNFα reaching max-
imal release first. We examined the relationship between
the levels of TNFα released at 6 hrs and the levels of the
other cytokines measured at 24 hrs (Figures 3A, B and
3C). The resultant data indicated that the amount of TNFα
released at 6 hrs could be used to predict IL-6, CXCL8 and
IL-10 release at 24 hrs.
If TNFα is a key initiating step in the inflammatory cas-
cade, then removal of TNFα should arrest or attenuate
subsequent cytokine release. Pre-treatment of explants
with a TNFα neutralising antibody (nTNFα Ab) for 1 hr
before LPS stimulation reduced the release of IL-6 and
CXCL8 back to baseline levels and the effect was still evi-
dent at 48 hrs post stimulation compared to treatment
with an isotype control and LPS (figures 3D &3E). Pre-
treatment with nTNFα Ab also completely abrogated the
release of IL-10 up to 48 hrs after LPS stimulation (figure
3F).Respiratory Research 2008, 9:47 http://respiratory-research.com/content/9/1/47
Page 5 of 14
(page number not for citation purposes)
Co-localisation of TNFα with macrophages and mast cells 
in response to LPS
As we demonstrated in figure 1A that the release of TNFα
was statistically elevated after 1 hour of LPS exposure it
was important to determine which cell/cells were respon-
sible for this early TNFα release. The cellular source of
TNFα was analysed in 18 subjects (9F/9M) of the study
consisting of 8 current, 7 ex and 3 non-smokers with a
range of lung functions (FEV1 % predicted 55 – 92%). To
determine the inflammatory cell types responsible for
TNFα release, serial sections were stained for TNFα and
one of the following cell markers: neutrophil elastase
(neutrophils), CD68 (macrophages), or mast cell tryptase
(mast cells). All sections stained positively for varying
amounts of neutrophil elastase, CD68 and mast cell tryp-
tase. Figure 4 shows a representative section of lung paren-
chyma from a 65-year-old female smoker (FEV1  83%
predicted), immuno-stained with anti-TNFα monoclonal
antibody after 1 hr exposure to LPS (see figure 4A and 4C)
and the serial sections stained for CD68 (see figure 4B)
and mast cell tryptase (see figure 4D). Co-localisation of
TNFα occurred in association with macrophages and mast
cells after 1 hr of exposure to LPS, and was consistent for
all individuals studied. TNFα did not co-localise with neu-
trophil elastase staining. We also analysed tissue follow-
ing 6 hours of LPS exposure however we found no
difference in the cellular sources of TNF alpha. As shown
in table 2, within the parenchymal tissue collected we
found no statistically significant differences in the num-
bers and distribution of macrophages, mast cells or neu-
trophils within the tissue obtained from GOLDI/II
patients compared to individuals with normal lung func-
tion.
IL-10, a negative regulator of TNFα production
IL-10 has been shown to act as a negative regulator of
TNFα production [27,28]. We were therefore interested in
studying the effects of IL-10 and whether it was able to
regulate the release of TNFα. Pre-treatment with an IL-10
neutralising antibody (nIL-10Ab) for 1 hour before LPS
stimulation augmented the release of TNFα (figure 5A),
particularly at the later time points where we previously
observed maximal IL-10 release (figure 2C). Since neutral-
ising the activity of IL-10 resulted in augmented release of
TNFα, we next examined if there was a similar increase in
the release of any other cytokines involved in the inflam-
matory cascade. Pre-treatment with nIL-10 Ab also
resulted in a significantly augmented release of both IL-6
and CXCL8 at 24 hrs, which was maintained for at least 48
hrs (figures 5B &5C).
Severity of COPD influences cytokine release
We observed large variation in cytokine release between
individuals and therefore sought to assess if there was an
Kinetics of the acute inflammatory response in human lung tissue Figure 1
Kinetics of the acute inflammatory response in human lung tissue. Human lung tissue (n = 37) was stimulated with 
100 ng/ml LPS (filled circles) or buffer control (open circles). The release of (A) TNFα and (B) IL-1β into the supernatant was 
measured by commercial ELISA. Values shown are the mean ± SEM and are expressed as pg/mg of tissue, * indicates a p value 
< 0.05.
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association between lung function and cytokine release in
our explant model. Patients were classified into the fol-
lowing groups, normal lung function (n = 13), GOLD I (n
= 11) and GOLD II (n = 13) using the GOLD guide-
lines[23]. We observed that all patients showed a similar
level of TNFα release up to the 6 hr time point, however
at 24 hrs, TNFα release continued to increase in individu-
als classified as GOLD I and GOLD II (mean = 24.7 ± 3.3
and 27.6 ± 4.2 pg/mg of tissue respectively), when com-
pared to patients with normal lung function (mean = 13.7
± 2.1 pg/ml of tissue, P < 0.05; figure 6A). By 48 hrs TNFα
release plateaued in all groups. Release of IL-6 and CXCL8
followed a similar pattern to that observed for TNFα with
GOLD II explants releasing elevated levels of these medi-
Cytokine cascades in the acute inflammatory response Figure 2
Cytokine cascades in the acute inflammatory response. Human lung tissue (n = 37) was stimulated with 100 ng/ml LPS 
(filled circles) or buffer control (open circles). The supernatants were analysed for (2A) IL-6, (2B) CXCL8, (2C) IL-10 and (2D) 
IL-5 using commercially available ELISAs. For all values are the mean ± SEM and are expressed as pg/mg tissue. * indicates p < 
0.05.
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TNFα, the key cytokine in the inflammatory response Figure 3
TNFα, the key cytokine in the inflammatory response. Data from figures 1A and 2A, B, and 2C were re-plotted to ana-
lyse the relationship between TNFα release at 6 hrs and IL-6 (3A), CXCL8 (3B) and IL-10 (3C) release at 24 hrs. Data was ana-
lysed using Spearman rank correlation, the values given are the Rho and p < 0.05. To confirm the role of TNFα in the cytokine 
cascade human lung tissue (n = 37) was pre-treated with neutralising TNFα antibody (nTNFαAb) (grey circles) or an isotype 
control (open circles) for 1 hr and then stimulated with 100 ng/ml LPS (filled circles). The supernatants were analysed for IL-6 
(3D), CXCL8 (3E), and IL-10 (3F) using commercial ELISAs. For all values given are the mean ± SEM and are expressed as pg/
mg of tissue * indicates a P value < 0.05.Respiratory Research 2008, 9:47 http://respiratory-research.com/content/9/1/47
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Co-localisation of TNFα with macrophages in the lung parenchyma Figure 4
Co-localisation of TNFα with macrophages in the lung parenchyma. Lung tissue was obtained from a 65 year-old 
female smoker (GOLD 1) stimulated with LPS for 1 hour. The tissue was then embedded and sequential sections of the lung 
parenchyma stained with monoclonal antibodies for TNFα (figure 4A and 4C) and CD68 (4B) and mast cell tryptase (4D). 
Staining specificity was determined by IgG1 isotype antibody controls 1:200 (4E) and 1:1000 (4F) for CD68 and mast cell tryp-
tase respectively. Bars represents 10 μm, positive cells are stained red.Respiratory Research 2008, 9:47 http://respiratory-research.com/content/9/1/47
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ators at 24 and 48 hrs (figures 6C and 6D). In contrast, IL-
10 release from GOLD I (mean = 8.5 ± 2.7 pg/mg of tis-
sue) and GOLD II patients (mean = 7.8 ± 1.8 pg/mg of tis-
sue) was actually lower compared to patients with normal
lung function (mean = 17.9 ± 3.1 pg/mg of tissue, P <
0.05) (see figure 6B). Importantly for all of the patient
demographic data collected including age, gender, and
smoking status these data did not influence cytokine
release in response to LPS.
Discussion
In this study, we have employed an ex vivo lung explant
model to investigate the initial acute inflammatory
response initiated by exposure to Gram negative bacterial
cell wall component LPS in lung tissue derived from
COPD patients and normal individuals. We demonstrate
that lung explants obtained from COPD patients classi-
fied with mild to moderate airflow obstruction (GOLD I
and II) release elevated concentrations of pro-inflamma-
tory cytokines TNFα, IL-6 and CXCL8 in response to LPS
but failed to mount an appropriate anti-inflammatory IL-
10 response when compared to normal lung tissue. We
suggest that these findings may have important clinical
implications for the pathogenesis of COPD as dysregu-
lated resolution of inflammation by IL-10 could account
for the exaggerated inflammation observed in COPD
patients during episodes of exacerbation.
The association between bacterial colonization and the
development and progression of airway inflammation in
COPD has been a subject of study for several years[29,30].
Although bacteria such as H. influenzae have been associ-
ated with COPD exacerbation, early studies have provided
conflicting results as to its isolation during exacerbation
[12-15]. Later evidence for the role of bacteria in COPD
exacerbations has come from antibiotic therapy studies.
Hill and colleagues in a large COPD study showed that
the airway bacterial load was related to inflammatory
markers and that the bacterial species present was related
to the degree of inflammation[31]. Although the subse-
quent inflammatory response following a bacterial infec-
tion is considered to play a key role in the pathogenesis of
COPD, the nature and sequence of the cytokine networks
involved in an exacerbation have remained unexplored.
The majority of clinical studies have previously concen-
trated on examining the acute inflammatory response
during exacerbations of COPD patients using induced
sputum and bronchial alveolar lavage (BAL) fluid. To our
knowledge this is the first study to compare explants from
patients with characterised COPD and individuals with
normal lung function to investigate the kinetics of the
acute inflammatory cytokine response within the distal
lung towards LPS, a bacterial wall component. LPS is a
widely used stimulus that acts on a number of cells within
the lung through well-defined signalling cascades [32-34].
Within the literature the typical dose of LPS used in cell
culture experiments and rodent models of airways disease
IL-10, a negative regulator of TNFα production Figure 5
IL-10, a negative regulator of TNFα production. 
Human lung tissue (n = 37) was pre-treated with neutralising 
IL-10 antibody (nIL-10Ab) (grey circles) or an isotype control 
(open circles) for 1 hr and then stimulated with 100 ng/ml 
LPS (filled circles). The supernatants were analysed for (A) 
TNFα, (B) IL-6, and (C) CXCL8 using commercially available 
ELISAs. Values given are the mean ± SEM and are expressed 
as pg/mg of tissue, * indicates a P value < 0.05.
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is 1 μg/ml [35-37]. We carried out dose response curves
for LPS on the tissue and deliberately chose a sub-maxi-
mal concentration of LPS 0.1 μg/ml in order to explore
cytokine release and interactions on a number of cells
within the lung explants.
In our model of acute inflammation in human lung tissue
we found that TNFα, IL-6 and CXCL8 were released fol-
lowing stimulation with LPS. This model using LPS mim-
ics the cytokine profile previously reported by several
groups in COPD patients with bacterial infections. In par-
ticular Solar and colleagues showed that the presence of
potentially pathogenic organisms in the bronchoaleolar
lavage from COPD patients was associated with a greater
degree of neutrophillia and higher TNFα levels[13].
Indeed several studies have confirmed that higher bacte-
rial load is associated with greater airway inflammation
measured by elevated TNFα, IL-6 and CXCL8 in BAL fluid
from COPD patients[13,38]. Additionally several exacer-
bation studies have reported elevated levels of TNFα, IL-6
and CXCL8 in induced sputum from COPD patients
admitted to hospital following an exacerbation[9,39].
Although bacterial load was not assessed in these exacer-
bation studies the cytokines reported, TNFα, IL-6 and
CXCL8 are the same cytokines that we observe in our
acute inflammatory model using LPS. The advantage of
this model over in vivo studies is that we have been able to
determine the kinetic profile of release of the cytokines
most reportedly elevated in COPD patients during exacer-
bations.
Severity of COPD influences cytokine release Figure 6
Severity of COPD influences cytokine release. Using the GOLD guidelines the 37 individuals in this study were classified 
as GOLD I (grey circles) and GOLD II (filled circles) or subjects with normal lung function (open circles). Data from figures 1A, 
2A, 2B and 2C were then re-analysed to determine the kinetics of (A) TNFα, (B) IL-10, (C) IL-6 and (D) CXCL8 release from 
the lung tissue of the patients in the three classified groups. Values given are the mean ± SEM and are expressed as pg/mg of tis-
sue, † indicates P < 0.05 for both GOLD I and GOLD II compared to GOLD 0, and * indicates P < 0.05 for GOLD II compared 
to GOLD 0.Respiratory Research 2008, 9:47 http://respiratory-research.com/content/9/1/47
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Classification of the patients in our study using the GOLD
guidelines for COPD diagnosis allowed us to segregate
patients into those with normal lung function and those
with mild (GOLD I) and moderate (GOLD II) COPD[23].
Using this approach, we found that lung explants from
patients with GOLD I and II status had an elevated TNFα
and subsequent IL-6 and CXCL8 response compared to
explants obtained from patients with normal lung func-
tion. Our data therefore suggests that the parenchyma tis-
sue of an individual with COPD would respond with an
enhanced inflammatory response following exposure to
LPS. The relationship between the magnitude of the
inflammatory response and disease severity in our study
may therefore have important clinical implications.
Recent findings indicate that some patients with COPD
develop frequent exacerbations, and recurrent exacerba-
tions may be associated with increased airway inflamma-
tion. Indeed Bhowmik et al.,[17] reported that COPD
patients with elevated concentrations of IL-6 and CXCL8
in sputum were more likely to have frequent exacerba-
tions, which is thought to lead to the rapid decline of lung
function in these patients. In support of these findings
other studies have also demonstrated a negative correla-
tion between FEV1  and the levels of TNFα, IL-6 and
CXCL8 in sputum[39] and BAL fluid[13,38]. These in vivo
studies therefore provide biological significance to our
findings that release of TNFα, IL-6 and CXCL8 from
explants in vitro negatively correlates with patients lung
function. Altogether the data suggests that the heightened
inflammatory response in both our model and in vivo
studies of exacerbations may lead to the accelerated
decline in lung function observed in COPD patients and
therefore has prognostic importance for the disease. In
support of these finding Donaldson and colleagues have
previous reported that exacerbations in moderate to
severe COPD patients contribute a greater extent to the
accelerated decline in FEV1 per year observed in these
patients[40]. In addition to the role of exacerbations in
COPD progression the work of Hurst and colleagues has
recently raised important awareness to the impact exacer-
bations have on systemic inflammation as they have
shown that the degree of systemic inflammation observed
in COPD patients is related to the extent of lower airway
inflammation during exacerbation[41]. These data bring
focus to the accumulating evidence of extra pulmonary
manifestations in COPD including cachexia and systemic
inflammation which are observed in severe COPD
patients. In our model of acute inflammation we observed
with disease severity elevated release of cytokines such as
IL-6 which could act systemically on the liver to promote
fibrinogen production. As raised levels of plasma fibrino-
gen is a independent risk factor of for cardiovascular dis-
ease[42]. Future studies using whole animal models
would therefore be useful to determine the role exacerba-
tion derived inflammatory mediators play in systemic
inflammation
In our study TNFα was the initial and predictive cytokine
released in the cascade following LPS exposure. Given the
heterogeneity of lung tissue obtained it was of interest to
characterize which cells were responsible for the TNFα
release in our model. Applying immunohistochemistry to
GMA sections, we found that macrophages and mast cells
accounted for the majority of TNFα positive cells follow-
ing LPS exposure. This finding is supported by previous
data showing that endotoxins of both Gram positive and
Gram negative bacteria stimulate TNFα release from both
these cell types[26,27]. Although we observed a 0.92 fold
increase in the number and distribution of TNFα positive
cells between GOLD I/II patients and controls this differ-
ence did not reach statistical significance. An extensive
small airway study by Hogg et al[43] has previously
reported that the percentage of airways positive for macro-
phages and neutrophils is elevated in the moderate to
severe stages of COPD. It is difficult to compare our obser-
vations due to the differences in atomical location of the
tissue analysed, small airways verses parenchyma and the
methodologies used and additonally mast cells were not
analysed in the Hogg et al study. Our investigations have
only been able to focus on a narrow window of the disease
spectrum due to the nature of patients undergoing surgery
and therefore we are unable to include GOLD III and IV
patients. Therefore it is difficult to determine if the
increase in the numbers of macrophages with increasing
COPD severity is responsible for the elevated levels of
TNFα observed or that macrophages and mast cells in
COPD patients have an exaggerated TNFα response due to
pre-sensitisation. Indeed it has been shown that pre-sensi-
tisation with LPS promotes an exaggerated Th1 cytokine
response in mouse models of allergic asthma[44]. Future
studies are therefore required to determine if pre-sensitisa-
tion of lung tissue to bacterial agents is related to the
degree of inflammation observed in COPD patients[31].
If TNFα is a key cytokine in acute airway inflammation
then neutralising its biological activity could provide an
important therapeutic treatment if given early enough
after a COPD exacerbation. Indeed, in our model inhibi-
tion of TNFα activity prevented the release of IL-6, CXCL8
and IL-10 following LPS exposure. Blockade of TNFα
activity using monoclonal antibodies or the soluble TNFα
receptor has been used as an effective therapy in rheuma-
toid arthritis, inflammatory bowel disease and severe
asthma [19-21]. However published reports of two clini-
cal trials which examined the effects of the chimeric mon-
oclonal TNFα antibody infliximab (Remicade) in COPD
patients found no improvement in symptoms, lung func-
tion or reduction of inflammation in induced spu-
tum[45,46]. The failure of anti-TNFα therapies may reflectRespiratory Research 2008, 9:47 http://respiratory-research.com/content/9/1/47
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the fact that COPD is a highly complex inflammatory dis-
ease in which many mediators are involved. However, the
substantial increase in TNFα production following LPS
exposure in our model and in vivo exacerbation studies
suggests that the role of TNFα may be more predominant
in acute inflammatory episodes rather than in the chronic
disease process. Therefore future studies maybe better
focused on the roles of anti-TNF therapies in preventing or
modifying the severity of acute exacerbations.
Several studies have shown that IL-10 acts as a classical
negative feedback inhibitor on TNFα release from macro-
phages[27,47]. In support of this mechanism of action,
we report that neutralization of IL-10 activity significantly
augmented LPS stimulated TNFα release from lung
explants. Release of IL-6 and CXCL8 were also shown to
be augmented following IL-10 inhibition, although this
was likely a direct result of the increased levels of TNFα.
We also show that IL-10 release was completely abolished
by neutralisation of the initial cytokine in the cascade,
TNFα. This supports a role for a delicate cytokine balance
between pro-inflammatory TNFα and anti-inflammatory
IL-10 in both resolution of inflammation and normal
homeostasis of the lung. Our finding that lung tissue from
GOLD I and GOLD II COPD patients releases decreased
levels of IL-10 in LPS derived acute inflammation com-
pared to patients with normal lung function has potential
important pathophysiologic relevance. In support of our
finding Takanashi et al[48] have also reported evidence of
IL-10 disregulation in COPD as they demonstrated that
the level of IL-10 in sputum from COPD patients is
decreased in comparison with healthy non-smokers. As
decreased expression of the anti-inflammatory mediator
IL-10 could lead to the enhanced TNFα released observed
in the COPD explants in this study. This raises important
questions as to the balance of pro and anti-inflammatory
mediators released within the lung during exacerbations
and their cause or effect relationship to the inflammatory
profile observed in COPD. One possible mechanism for
altered IL-10 gene expression could be single nucleotide
polymorphisms (SNP) within the gene. To date no con-
sensus has been reached regarding any IL-10 SNP in the
progression of COPD. Alternatively IL-10 gene expression
could be altered epigenetically due to environmental
insults such as cigarette smoke or the oxidants released in
response to smoke exposure. Future studies will hopefully
provide more information as to the mechanisms and out-
comes involved in these modifications and their role in
disease progression. As therapeutic approaches aimed at
preventing the inflammatory cascade in COPD are cur-
rently focused on pro-inflammatory mediators, anti-
inflammatory interventions could therefore be equally if
not more important. Since IL-10 is able to ameliorate the
release of TNFα in acute inflammation, therapeutic strate-
gies which enhance the endogenous release or activity of
IL-10 could be used to dampen TNFα responses without
compromising the immune system, providing important
targets as new therapeutic strategies for a major clinical
unmet need.
Due to the nature of COPD exacerbations it is technically
difficult to investigate the kinetics of acute inflammatory
events within the lung following admission of patients to
hospital. In this ex vivo lung explant model, we have been
able to interrogate further the acute inflammatory profile
in terms of the tissue's response to LPS. The use of lung
explants has several advantages over isolated cell cultures,
including preservation of normal tissue architecture and
cellular interactions. In addition, explants can be manip-
ulated to dissect the role of various resident cells and spe-
cific cytokines they release using neutralizing antibodies.
Using this model we have been able to clarify the intrinsic
response of resident cells within the lung tissue following
LPS exposure and eliminate the contribution of cytokine
release from circulating cells. Therefore the model also has
some disadvantages as it does not entirely mimic the in
vivo situation as we have not studied the role of recruited
inflammatory cells following LPS exposure. Another dis-
advantage is the fact that lung explants are extremely het-
erogenous between individuals especially COPD patients,
and we have tried to account for this by selecting 6
explants randomly per experimental condition. Addition-
ally all of the explants used were dissected free of small
airways and therefore the model does not represent the
contribution of small airways following LPS exposure.
Other causes of COPD exacerbations include viruses and
common pollutants; the role of bacterial-viral or bacterial-
pollutant interactions may exist and have not been inves-
tigated in this study.
Conclusion
In summary, we report on a reliable ex vitro model for the
investigation of acute lung inflammation and its resolu-
tion using lung parenchymal explants from COPD
patients. Using this model, we propose that differences in
the production of both TNFα and IL-10 in COPD lung tis-
sue following exposure to bacterial endotoxin LPS may
have important biological implications for both episodes
of exacerbation, disease progression and amelioration.
Thus further work is required to determine the role of bac-
terial colonization, exacerbations and airway inflamma-
tion in the pathogenesis of COPD.
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